Limits...
Comparison of 99mTc-3PRGD2 integrin receptor imaging with 99mTc-MDP bone scan in diagnosis of bone metastasis in patients with lung cancer: a multicenter study.

Miao W, Zheng S, Dai H, Wang F, Jin X, Zhu Z, Jia B - PLoS ONE (2014)

Bottom Line: Three experienced nuclear medicine physicians blindly read the 99mTc-3PRGD2 and 99mTc-MDP images.Eighty-nine bone lesions in 18 patients were diagnosed as metastases and 23 bone lesions in 9 patients were benign.In a lesion-based analysis, 99mTc-3PRGD2 imaging demonstrated a sensitivity, specificity, and accuracy of 92.1%, 91.3%, and 92.0%, respectively.

View Article: PubMed Central - PubMed

Affiliation: Department of Nuclear Medicine, the 1st Affiliated Hospital of Fujian Medical University, Fuzhou, China.

ABSTRACT

Purpose: 99mTc-3PRGD2, a promising tracer targeting integrin receptor, may serve as a novel tumor-specific agent for single photon emission computed tomography (SPECT). A multi-center study was prospectively designed to evaluate the diagnostic accuracy of 99mTc-3PRGD2 imaging for bone metastasis in patients with lung cancer in comparison with the conventional 99mTc-MDP bone scan.

Methods: The patients underwent whole-body scan and chest tomography successively at both 1 h and 4 h after intravenous injection of 11.1 MBq/Kg 99mTc-3PRGD2. 99mTc-MDP whole-body bone scan was routinely performed within 1 week for comparison. Three experienced nuclear medicine physicians blindly read the 99mTc-3PRGD2 and 99mTc-MDP images. The final diagnosis was established based on the comprehensive assessment of all available data.

Results: A total of 44 patients (29 male, 59±10 years old) with suspected lung cancer were recruited from 4 centers. Eighty-nine bone lesions in 18 patients were diagnosed as metastases and 23 bone lesions in 9 patients were benign. In a lesion-based analysis, 99mTc-3PRGD2 imaging demonstrated a sensitivity, specificity, and accuracy of 92.1%, 91.3%, and 92.0%, respectively. The corresponding diagnostic values for 99mTc-MDP bone scan were 87.6%, 60.9%, and 82.1%, respectively in the same patients. 99mTc-MDP bone scan had better contrast in most lesions, whereas the 99mTc-3PRGD2 imaging seemed to be more effective to exclude pseudo-positive lesions and detect bone metastases without osteogenesis.

Conclusion: 99mTc-3PRGD2 is a novel tumor-specific agent based on SPECT technology with a promising value in diagnosis of bone metastasis in patients with lung cancer.

Trial registration: ClinicalTrials.gov NCT01737112.

Show MeSH

Related in: MedlinePlus

Comparison of 99mTc-3PRGD2 SPECT, 99mTc -MDP bone scan, and 18F-FDG PET in a 60 year-old patient with a recent fall-down trauma.The99mTc -MDP bone scan was positive (red arrows), whereas both 99mTc-3PRGD2 SPECT and 18F-FDG PET were negative. A: 99mTc-3PRGD2 WB (-), B: 99mTc-3PRGD2 SPECT (−), C: 99mTc-MDP bone scan (+), D: 18F-FDG PET (−). WB: whole body.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4206469&req=5

pone-0111221-g002: Comparison of 99mTc-3PRGD2 SPECT, 99mTc -MDP bone scan, and 18F-FDG PET in a 60 year-old patient with a recent fall-down trauma.The99mTc -MDP bone scan was positive (red arrows), whereas both 99mTc-3PRGD2 SPECT and 18F-FDG PET were negative. A: 99mTc-3PRGD2 WB (-), B: 99mTc-3PRGD2 SPECT (−), C: 99mTc-MDP bone scan (+), D: 18F-FDG PET (−). WB: whole body.


Comparison of 99mTc-3PRGD2 integrin receptor imaging with 99mTc-MDP bone scan in diagnosis of bone metastasis in patients with lung cancer: a multicenter study.

Miao W, Zheng S, Dai H, Wang F, Jin X, Zhu Z, Jia B - PLoS ONE (2014)

Comparison of 99mTc-3PRGD2 SPECT, 99mTc -MDP bone scan, and 18F-FDG PET in a 60 year-old patient with a recent fall-down trauma.The99mTc -MDP bone scan was positive (red arrows), whereas both 99mTc-3PRGD2 SPECT and 18F-FDG PET were negative. A: 99mTc-3PRGD2 WB (-), B: 99mTc-3PRGD2 SPECT (−), C: 99mTc-MDP bone scan (+), D: 18F-FDG PET (−). WB: whole body.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4206469&req=5

pone-0111221-g002: Comparison of 99mTc-3PRGD2 SPECT, 99mTc -MDP bone scan, and 18F-FDG PET in a 60 year-old patient with a recent fall-down trauma.The99mTc -MDP bone scan was positive (red arrows), whereas both 99mTc-3PRGD2 SPECT and 18F-FDG PET were negative. A: 99mTc-3PRGD2 WB (-), B: 99mTc-3PRGD2 SPECT (−), C: 99mTc-MDP bone scan (+), D: 18F-FDG PET (−). WB: whole body.
Bottom Line: Three experienced nuclear medicine physicians blindly read the 99mTc-3PRGD2 and 99mTc-MDP images.Eighty-nine bone lesions in 18 patients were diagnosed as metastases and 23 bone lesions in 9 patients were benign.In a lesion-based analysis, 99mTc-3PRGD2 imaging demonstrated a sensitivity, specificity, and accuracy of 92.1%, 91.3%, and 92.0%, respectively.

View Article: PubMed Central - PubMed

Affiliation: Department of Nuclear Medicine, the 1st Affiliated Hospital of Fujian Medical University, Fuzhou, China.

ABSTRACT

Purpose: 99mTc-3PRGD2, a promising tracer targeting integrin receptor, may serve as a novel tumor-specific agent for single photon emission computed tomography (SPECT). A multi-center study was prospectively designed to evaluate the diagnostic accuracy of 99mTc-3PRGD2 imaging for bone metastasis in patients with lung cancer in comparison with the conventional 99mTc-MDP bone scan.

Methods: The patients underwent whole-body scan and chest tomography successively at both 1 h and 4 h after intravenous injection of 11.1 MBq/Kg 99mTc-3PRGD2. 99mTc-MDP whole-body bone scan was routinely performed within 1 week for comparison. Three experienced nuclear medicine physicians blindly read the 99mTc-3PRGD2 and 99mTc-MDP images. The final diagnosis was established based on the comprehensive assessment of all available data.

Results: A total of 44 patients (29 male, 59±10 years old) with suspected lung cancer were recruited from 4 centers. Eighty-nine bone lesions in 18 patients were diagnosed as metastases and 23 bone lesions in 9 patients were benign. In a lesion-based analysis, 99mTc-3PRGD2 imaging demonstrated a sensitivity, specificity, and accuracy of 92.1%, 91.3%, and 92.0%, respectively. The corresponding diagnostic values for 99mTc-MDP bone scan were 87.6%, 60.9%, and 82.1%, respectively in the same patients. 99mTc-MDP bone scan had better contrast in most lesions, whereas the 99mTc-3PRGD2 imaging seemed to be more effective to exclude pseudo-positive lesions and detect bone metastases without osteogenesis.

Conclusion: 99mTc-3PRGD2 is a novel tumor-specific agent based on SPECT technology with a promising value in diagnosis of bone metastasis in patients with lung cancer.

Trial registration: ClinicalTrials.gov NCT01737112.

Show MeSH
Related in: MedlinePlus